What clinical trials support remission of type 2 diabetes through low-calorie diets?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Randomized controlled trials and large pragmatic studies show that very-low-calorie and low-calorie dietary programs can induce remission of type 2 diabetes (T2D) in a substantial minority of participants—typical RCT remission rates cited are roughly 40–60% with 800–853 kcal/day interventions and nearly half at 1 year in some large programs [1] [2]. The Diabetes Remission Clinical Trial (DiRECT) and subsequent trials using total diet replacement (≈825–853 kcal/day) provide the longest and strongest randomized evidence, with multi‑year follow‑up showing durable remission tied to sustained weight loss [3] [4].
1. The main randomized trials that anchor the claim: DiRECT and similar VLCD RCTs
The best‑known randomized evidence is DiRECT, a primary care–led cluster RCT that used total diet replacement (~825–853 kcal/day for 12–20 weeks), stepped food reintroduction and structured weight‑loss maintenance; DiRECT showed clinically important remission rates and has extended follow‑up to five years demonstrating benefits when weight loss was maintained [3] [4]. Systematic and narrative reviews and trial tables summarize multiple VLCD/meal‑replacement RCTs aiming for remission, and cite remission rates in RCTs of roughly 40–60% with 800–853 kcal/day programs [1] [5] [6].
2. What the newer 2024–2025 literature adds: generalizability and other designs
Recent trials and real‑world programs expand the evidence beyond the UK DiRECT setting. A 6‑month Chinese intervention using 815–835 kcal/day total replacement showed remission and metabolic improvements and identified predictors of nonresponse (longer diabetes duration, higher fat mass, lower beta‑cell function) [7] [1]. National programs such as the NHS Type 2 Diabetes Path to Remission have implemented VLCD approaches at scale and reported real‑world remission though at lower rates than RCTs [4].
3. Intermittent and low‑carbohydrate permutations: RCT signals, but mixed context
Randomized trials of intermittent calorie restriction (ICR) and low‑carbohydrate digitally supported programs report improvements and some remission outcomes. Authors state that RCTs have demonstrated ICR can lead to remission [8]. A 2025 RCT of a low‑carbohydrate digitally supported weight‑loss program showed improvements in glycemic control over 12 months [9]. Systematic reviews also note that carbohydrate‑restricted diets combined with calorie restriction produce higher remission rates than low‑carb alone [10].
4. Effect sizes and who benefits most
Across cited trials, the strongest predictor of remission is weight loss magnitude and short diabetes duration. DiRECT and related analyses report that maintenance of ≥10 kg weight loss predicts durable remission—one extension found that 81% of those who kept >10 kg off at two years were in remission [3]. The Chinese study and other cohorts flagged shorter diabetes duration, better beta‑cell function and greater insulin sensitivity as determinants of success [7] [1].
5. Real‑world implementation and limitations of trial evidence
Implementation studies show lower remission rates in routine care compared with RCTs and significant challenges in sustaining weight loss at scale [4] [11]. Reviews emphasize that many VLCD trials focused on weight loss rather than remission as a primary endpoint and that long‑term maintenance and monitoring (including drug withdrawal under supervision) are essential [6] [5].
6. Competing viewpoints and clinical nuance
Some commentators call for re‑examining the remission concept and stress patient‑centric definitions, noting that remission may be temporary and dependent on ongoing weight control [12]. Others highlight the need for interdisciplinary teams and structured follow‑up to achieve remission safely in practice [11]. Trials combining pharmacotherapy with calorie restriction (e.g., dapagliflozin plus calorie restriction) are being evaluated, indicating debate over whether drugs should augment or be replaced by dietary programs [12].
7. Practical takeaways for clinicians and patients
Controlled trials show that structured very‑low‑calorie programs (≈800–853 kcal/day, often meal‑replacement‑based) can put a significant fraction of people with recent‑onset T2D into remission, with best outcomes in those who lose and keep off substantial weight [3] [1]. Real‑world programs can reproduce benefits but at lower rates and with greater implementation challenges; careful medical supervision—especially for medication withdrawal and monitoring—is required [4] [6].
Limitations: available sources do not mention every individual RCT by name beyond DiRECT and several cited trials; full trial lists are summarized in review tables referenced in the sources [5] [6].